Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus SEREVENT.
ISOETHARINE HYDROCHLORIDE vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist